This website uses cookies

This website uses cookies to ensure you get the best experience. By using our website, you agree to our Privacy Policy

International In-house Counsel Journal logoInternational In-house Counsel Journal logo

Different Approaches to Pricing and Reimbursement of Innovative Pharmaceutical Products in Europe

Abstract

All aspects of the pharmaceutical market are heavily regulated due to the major public health implications related to the use of pharmaceutical products. Pricing and reimbursement of pharmaceutical products is the area posing the greatest level of challenge to pharmaceutical and biotech firms operating on a multinational basis. Each individual country is governed by its own pricing and reimbursement rules and procedures and - despite European legislation mandating transparency of decisions and harmonized timelines - the outcome of the various national pricing and reimbursement processes may vary dramatically both in terms of timing and results.

Read Paper

Author

Renato Dellamano
President, Value Vector, Italy

Renato Dellamano is the President of ValueVector, a consulting agency he founded in 2003 that provides strategic advice to companies operating in the healthcare field. One of the top experts worldwide in the field of pharmaceutical and biotech pricing and reimbursement, he accumulated more than twenty years of extensive business experience in the healthcare industry. Prior to founding ValueVector, Renato was the global Head of Strategic Pricing at the Headquarters of the Swiss pharmaceutical company Hoffmann-La Roche, in Basel. In the seven years he held this position, he was instrumental in developing global pricing and reimbursement strategies for pharmaceutical products in all the disease areas Roche had an interest in, including internally developed and in-licensed projects. Before heading the Strategic Pricing function, he spent almost two years as Global Controller of the Pharma Division of Hoffmann-La Roche, with responsibility on the Europe-Africa region. Previously, Renato had held senior managerial positions at the Italian Affiliate of Hoffmann-La Roche, in Milan, where – between 1989 and 1994 – he headed the Strategic Planning, the Pricing and Reimbursement and the Business Development functions. A Health Economist and a former professor of Hospital Management, he holds a degree in economics from the Bocconi University of Milan and specialized in Health Economics at the CERGAS - Center for Research on Health Care Management, in Milan.

Company

Value Vector

Related Papers

Blocking Effect of the Blocking Act?
The Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch Waxman Act 1984, was enacted in 1984 to balance the privileges offered to brand...Read more
Portrait image of Anagha Tendulkar
Anagha Tendulkar
In-house Patent Counsel, Cipla, India
An Effective, Practical Approach to International Competition Law Compliance
The traditional approach to antitrust or competition law compliance is to start with the parade of horribles that can flow from a violation (jail, fines, damages, bad press), then stress...Read more
Portrait image of Kent Bernard
Kent Bernard
Member, Bar of the Commonwealth of Pennsylvania, U.S.A., Kent Bernard, USA
Applicability of Deal Value Threshold in Share Swap Transactions in India
The Competition Commission of India (“CCI”) has embarked on a transformative journey to enhance its merger control framework, with pivotal changes taking effect on 10 September 2024. These reforms arise...Read more
Portrait image of Prateek Sethi
Prateek Sethi
Associate Vice President - Legal, Bharti Airtel Limited, India
Payback Time: Trump and EU’s “Exorbitant” Fines vs US Tech Companies
The election of Donald Trump for a second term of the US Presidency is of considerable concern to the European Union (EU), NATO, and states worldwide in general owing to...Read more
Portrait image of Roy Girasa
Roy Girasa
Professor of Law, Pace University, USA